Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

Barbara Burtness, MD
Published: Monday, Aug 07, 2017



Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Although immunotherapy can lead to durable responses, there are still a population of patients who do not see any responses, explains Burtness.

According to Burtness, more research needs to be conducted in an attempt to make all patients respond to immunotherapy or to determine a targeted therapy to better support the immune system.
 
SELECTED
LANGUAGE


Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Although immunotherapy can lead to durable responses, there are still a population of patients who do not see any responses, explains Burtness.

According to Burtness, more research needs to be conducted in an attempt to make all patients respond to immunotherapy or to determine a targeted therapy to better support the immune system.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x